News

Timber Pharmaceuticals Announces Appointment of Dr. David Cohen and Dr. Lubor Gaal to Board of Directors

SmallCaps Daily August 19, 2020

221 3 minutes read

WOODCLIFF LAKE, NJ – (NewMediaWire) – August 19, 2020 – Timber Pharmaceuticals, Inc. (“Timber” or the
“Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the
development and commercialization of treatments for orphan dermatologic
diseases, today announced the appointment of David Cohen, M.D. and Lubor Gaal,
Ph.D. to its board of directors.

“We continue to add
expertise and talent in the areas of drug development and delivery to our team
at Timber and welcome Dr. Cohen and Dr. Gaal to the Board,” said John Koconis,
chief executive officer of Timber. “Dr. Cohen is a renowned dermatologist who
has contributed to the development of global treatment guidelines and has
played an important role in advancing research in many rare dermatologic
conditions. Meanwhile, Dr. Gaal has extensive experience as a biotech
entrepreneur with a successful track record in securing assets and executing
licensing and partnering transactions. We look forward to working closely with
both as we advance our clinical development pipeline.”

Dr. Cohen is the Charles
C. and Dorothea E. Harris Professor of Dermatology at New York University
School of Medicine, where he also serves as Chief of Allergy and Contact
Dermatitis, Vice Chairman of Clinical Affairs, and Director of Occupational and
Environmental Dermatology. He was a founding board member for the American Acne
and Rosacea Society and previously served as President of the American
Dermatological Association, the American Contact Dermatitis Society, the
Dermatology Section of the New York Academy of Medicine, and the New York
Dermatological Association. Dr. Cohen has also served on numerous boards
including Kadmon, Dermira, Vyteris, and Connetics. He received a B.S. in
biomedical science from the City University of New York, an M.D. from State
University of New York at Stony Brook School of Medicine, and an M.P.H. in
environmental science from Columbia University School of Public Health.

Dr. Gaal brings more than
two decades of business development, external innovation, and licensing
experience in biotechnology and biopharmaceuticals. He is currently Senior Vice
President and Head of Europe for Locust Walk where he is responsible for
executing licensing, M&A, and financing transactions for biopharma
companies around the globe. Dr. Gaal previously served as Head of External
Innovation and Licensing for Almirall and held various roles at Bristol-Myers
Squibb including Head of Europe, Global Search and Business Development. He has
also held executive management roles at NEURO3D, Vectron Therapeutics, Berlex
Laboratories, Burrill & Company, and Sandoz. Dr. Gaal has a B.Sc. in
Neurobiology from the University of Sussex and a Ph.D. in Neurosciences from
the University of California.

About Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals,
Inc. is a biopharmaceutical company focused on the development and
commercialization of treatments for orphan dermatologic diseases. The Company’s
investigational therapies have proven mechanisms-of-action backed by decades of
clinical experience and well-established CMC (chemistry, manufacturing and
control) and safety profiles. The Company is initially focused on developing
non-systemic treatments for rare dermatologic diseases including congenital
ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex
(TSC), and localized scleroderma. For more information, visit
www.timberpharma.com

Forward-Looking Statements

This press release
contains certain forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934 and Private Securities Litigation Reform Act, as amended, including those
relating to the Company’s product development, clinical and regulatory
timelines, market opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth opportunities and
other statements that are predictive in nature. These forward-looking
statements are based on current expectations, estimates, forecasts and
projections about the industry and markets in which we operate and management’s
current beliefs and assumptions.

These statements may be
identified by the use of forward-looking expressions, including, but not
limited to, “expect,” “anticipate,” “intend,”
“plan,” “believe,” “estimate,” “potential, “predict,”
“project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements relate to future
events or our financial performance and involve known and unknown risks,
uncertainties, and other factors which may cause actual results, performance or
achievements to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s Form 10-Q filed on August 18,
2020 and its other filings with the Securities and Exchange Commission.
Prospective investors are cautioned not to place undue reliance on such
forward-looking statements, which speak only as of the date of this press
release. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.